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The analysis of some extra- and intragenic markers within or closely linked to the cystic fibrosis transmembrane 
regulator (CFTR) gene is useful as a molecular method in clinical linkage analysis. Indeed, knowing that the 
molecular basis of cystic fibrosis (CF) is highly heterogeneous in our population, the study of haplotype association 
with normal and CF chromosomes could be very helpful in cases where one or both mutations remain unidentified. 
In this study, we analysed with PCR-RFLP and capillary electrophoresis some extra (pJ3.11, KM19 and XV2C) and 
intragenic (IVS8CA, IVS17bTA and IVS17bCA) polymorphic markers in 50 normal and 10 Tunisian patients 
carrying the rare E1104X mutation in order to determine the haplotype associated with this mutation. For the 
extragenic markers, 8 haplotypes were identified. The most frequent of them are the 221 and 112 accounting for 80% 
of total haplotypes. For the intragenic markers, five haplotypes were present on the E1104X chromosomes. One of 
them 16-31-13 accounted for 50%. To our knowledge, this is the first work to be interested to the haplotypes linked 
to the E1104X mutation. This preliminary study of haplotypes could be a helpful method to determine the molecular 
lesions responsible of this pathology.
Keywords: CF, E1104X mutation, haplotype, extragenic markers, intragenic mark
Cystic fibrosis (CF) is the most common lethal autosomal recessive disorder in Caucasian 
populations. The gene responsible for this disease, encodes a 1480 amino-acid protein called 
the cystic fibrosis transmembrane conductance regulator CFTR (13). Numerous mutations on 
this gene have been identified to be responsible for CF.
The most common defect is observed to be the F508 del mutation, deletion of 3 base pair 
in exon 10. In Tunisian population, 12 different CFTR mutations, accounting for 90% of CF 
alleles, have been found. The E1104X located in exon 17b, is the second mutation after the 
F508del mutation in our population, represents 16.18% of all CF mutations but it is a rare 
mutation in the world (9).
In populations with heterogeneous spectrum mutations, genetic analysis can be 
facilitated by haplotype study. 
The haplotypes associated with the CFTR mutations in the North African population 
remain unidentified. In this work we aimed to determine haplotypes associated with the 
E1104X mutation using 3 intragenic microsatellites (IVS8CA, IVS17bTA and IVS17bCA), 
and 3 extragenic markers (pJ3.11, KM19 and XV2C). The combination of both types of 
markers is expected to provide useful information regarding the origin and evolution of 
CFTR mutations (20).
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 Association of haplotype with a specific CFTR mutation would help to increase genetic 
informativity for prenatal diagnosis and carrier detection in many of studied families where 
one or no mutations are known.
Materials and Methods
This study included 10 CF pediatric patients, aged between 2 and 18 months. The selection 
was based on typical clinical manifestations of pulmonary and/or gastro-intestinal disease and 
high levels of sweat chloride concentration (higher than 60 mmol/l). The CFTR mutation was 
previously identified to be the E1104X mutation using DGGE and sequencing reaction (9).
A control group consisting of 50 healthy non-CF patients, aged between 2 months and 4 
years, was also studied.
All CF children and healthy controls parents participating in this study were informed in 
details about the study and informed consents were signed.
Genomic DNA of studied samples was extracted from peripheral blood with the classical 
salting-out protocol (16).
RFLP analysis
Extragenic markers (pJ3.11, KM19 and XV2C) were analyzed with restriction fragment 
length polymorphism (RFLP) procedure.
The pJ3.11 marker is located at 750 Kb of the 3’ end of the CFTR gene (6), the XV2C 
and KM19 markers are located 175 and 125 Kb up stream of the 5’ end of the CFTR gene 
(22).
RFLP allows to discriminate between two alleles at each marker based on the presence 
or the absence of a restriction site.
DNA was amplified using sequence primers previously described. (Table I) (6, 22). 
To analyze XV2C marker, the products were digested by TaqI restriction enzyme (22). 
For pJ3.11 and KM19 markers, amplified products were analyzed by PstI restriction enzyme 
(14, 22). PCR and restriction products were separated by electrophoresis on 2% agarose gel.
The extragenic haplotype construction was established using the standard nomenclature; 
the absence of the restriction site (–) corresponds to allele 1, and the presence of the restriction 
(+) site corresponds to allele 2 (8).
Table I. Sequences of primers used in the study of extragenic and intragenic markers 
Extragenic markers Intragenic markers
Markers Sequences Markers Sequences Fluorochrome
XV2C (F) 5’gttgaagtgaattgaatg3’
(R) 5’gttcaaactatgtcaaag3’
IVS8CA (F) 5’aaatctatctcatgttaatgctgaaga3’
(R) 5’actaagatatttgcccattatcaagtt3’
Fam
KM19 (F) 5’gctgcatcatataagttgcc3’
(R) 5’aaggctacactgttaatttt3’
IVS17bCA (F) 5’tgtcacctcttcatactcat 3’
(R) 5’aaacttaccgacaagaggaa 3’
Hex
pJ3.11 (F) 5’ccactgatactgtgagac3’
(R) 5’gttgtttcaagtcactgc 3’
IVS17bTA (F) 5’gctgcattctataggttatc3’
(R) 5’tgtgaaaacagggataatac3’
Fam
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Multiplex PCR
Intragenic markers IVS8CA (intron8), IVS17bTA and IVS17bCA (intron 17b) were analyzed 
by a multiplex PCR reaction. PCR were performed with 200 ng of DNA, 1X Master Mix 
(Promega) and 10 pmoles of each primer with fluorescent Hex or Fam phosphoramidites in a 
total volume of 14 µl. 
The primer sequences was previously described (Table I) (17, 26).
Capillary electrophoresis
PCR with thirty-five cycles for 1 min each at 90 °C, 57 °C and 72 °C were performed. 
Amplified products (1 µl) were mixed with 12µl deionised formamide and 1 µl of 500 
TAMRA Size standard (Applied Biosystems). Samples were denatured at 92 °C for 3min, 
then injected in ABI Prism 310 genetic analyzer (Applied Biosystems). Electrophoresis was 
performed in POP4polymer (Applied Biosystems), 15 Kv with 5 s injection time and 30 min 
electrophoresis time on a 47 cm 50 µm capillary (Applied Biosystems). After electrophoresis, 
fluorescence data was filtered and analysed using GeneScan analysis software version 3.1.2.
Each haplotype is named according to the number of repeats at loci IVS8CA, IVS17bTA 
and IVS17bca, respectively. 
Statistical analysis
Chi-square test was used to compare the haplotype association among CF patients and healthy 
individuals.
Results and Discussion
The E1104X mutation, initially discovered by Zielenski in a French-Canadian patient in 1992 
(http://www.genet.sickkids.on.ca/cftr/), consists of a single nucleotide substitution (G to T) at 
position 3442 in exon 17b, and causes introduction of a premature stop codon (GAA to TAA) 
at position 1104 in the protein sequence (27). 
The E1104X mutation was later described in Germany by Reiss in 1993 (21), in France 
(4, 23, 24), and in US (10). 
  This mutation is considered rare in the wordwide CF population but seems to be 
more frequent in our population with 16.18% of CF chromosomes (9).
The study of extragenic haplotypes associated with the E1104X allele revealed 8 
different haplotypes (Table II). Five of them were found in CF chromosomes as well as in 
normal ones (Table II). The other three haplotypes were encountered solely in healthy 
individuals. 
The 221 and 112 haplotypes accounting, respectively, for 45% and 35% of CF 
chromosomes haplotypes were significantly more frequent in this group than in healthy 
individuals (p = 0.00019, 0.006 respectively) (Table II).
Analysis of intragenic haplotypes established with microsatellites markers IVS8CA, 
IVS17bTA and IVS17bCA are shown in Table III. 
For the 120 analyzed chromosomes, 42 different haplotypes were described. Five 
haplotypes were observed in E1104X chromosomes. One of them (16-31-13), accounting for 
50%, was strongly associated to this mutation (p = 6.4 10–11) (Table III). 
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 Table II. Different extragenic haplotypes found in the 120 analyzed chromosomes
Haplotype name E1104X mutation Normal P
Number of chromosomes % Number of chromosomes %
221 9 45 11 11 0.00019
112 7 35 11 11 0.006
111 2 10 21 21 0.253 
222 1 5 23 23 0.066
211 1 5 8 8 0.641
121  – 10 10  
212  – 8 8  
122  – 8 8  
Total 20 100
Haplotype is named according to the absence (1) or presence (2) of restriction site at loci pJ3.11, KM19 and XV2C, 
respectively
A second haplotype (16-30-13) present only in CF chromosomes representing 20% 
appears also to be highly associated with this mutation (p = 0.00038) (Table III). Two other 
less frequent haplotypes (16-30-14 and 16-29-14) show significant association with CF 
chromosomes (p = 0.013 and 0.018 respectively) (Table III).
The multiple allelism of CF prevents the rapid and reliable diagnosis of the disease-
causing mutations in compound heterozygotes and non-F508del homozygotes. Knowledge 
of the population genetics and the chromosomal marker haplotype of the various CFTR 
mutations would significantly facilitate the mutation diagnosis in CF.
Microsatellites and single nucleotide polymorphisms (SNPs) have been described 
within the CFTR gene. Both types of markers can be used to trace the origin and evolution of 
the different CF mutations (1, 18, 19, 25). SNPs can be used to define the stable haplotypic 
frameworks on which CFTR mutations occurred. Microsatellite markers, which mutate faster 
and that are more diverse among chromosomes, can help to measure genetic variability 
within the CFTR locus and to estimate the age of CF mutations (1, 7, 15, 26). 
The most common CF mutations (F508del, G542X and N1303K), provide an exceptional 
opportunity for the analysis of association between microsatellite allelic systems and SNP’s. 
The patterns of haplotypes associated with these mutations should help in the understanding 
of the evolution of microsatellite loci and should help to define the anthropological time of 
the mutation (10). However, the haplotype analysis linked to rare mutation remains 
undetermined, that is why in this study we aimed to determine haplotypes associated with the 
E1104X mutation using some extra (pJ3.11, KM19 and XV2C) and intragenic (IVS8CA, 
IVS17bTA and IVS17bCA) polymorphic markers. We opted to combine six different markers 
for better informativity and for their strong association with CFTR gene (Fig. 1).
Our work is the first in the world to be interested to the study of the haplotype linked to 
the E1104X mutation. In fact, this mutation was observed in different populations from 
Canada, France, Germany and the US, with a low frequency excepted in Tunisian and Libyan 
populations where it represents 16.18% and 40%, respectively, of CFTR spectrum mutation 
(9, 11). We found it interesting to determine haplotypes associated with the E1104X mutation 
to provide information on the age and origin of this mutation. 
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Table III. Distribution of the microsatellites haplotypes among normal and CF chromosomes
Name of haplotype  E1104X mutation Normal  
PNumber of chromosomes % Number of chromosomes %
16-31-13 10 50 2 2 6.4 10–11
16-30-13 4 20 – – 0.00038
16-30-14 2 10 – – 0.013
16-29-14 2 10 1 1 0.018
22-31-14 2 10 4 4 0.261
17-07-17 – 13 13
23-31-13 – 6 6
 18-7-13 – 5 5
23-44-15 – 3 3
18-31-13 – 4 4
22-44-13 – 2 2
16-38-13 – 6 6
16-33-13 – 2 2
22-48-13 – 3 3
18-41-13 – 2 2
22-43-13 – 2 2
23-28-17 – 3 3
22-30-13 – 2 2
23-32-15 – 3 3
16-44-13 – 2 2
17-44-11 – 1 1 
18-29-16 – 1 1 
 19-7-17 – 4 4
22-33-13 – 3 3
16-41-17 – 1 1 
16-40-15 – 2 2
15-30-13 – 2 2
16-47-14 – 1 1
16-48-13 – 1 1
17-42-14 – 3 3
23-47-13 – 1 1 
16-33-15 – 2 2
16-40-17 – 1 1 
17-45-13 – 2 2
17-31-11 – 1 1 
18-31-15 – 1 1 
16-45-13 – 2 2
15-37-13 – 1 1 
17-41-13 – 2 2
23-44-11 – 1 1
16-40-11 – 1 1
22-35-17 – 1 1
Each haplotype is named according to the number of repeats at loci IVS8CA, IVS17bTA and IVS17bCA,  
respectively
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Fig. 1. Linkage Disequilibrium (LD) Plot of the CFTR gene from the Haploview software 4.2. 
Schematic diagram of the CFTR gene on chromosome 7. Exons are represented by vertical lines or Boxes.  
The diamond color indicates the level of LD; darker shades indicate a higher LD while lighter shades indicate 
lower LD and Grey regions represent missing data points
Statistical analysis showed difference between haplotypes distribution in normal and CF 
chromosomes. For the extragenic haplotype, E1104X mutation is associated in 80% of cases 
to both 221 and 112 haplotypes. However, these two haplotypes were observed only in 20% 
of normal population chromosomes (p = 0.00019, 0.006, respectively) (Table II).
The E1104X mutation revealed a heterogeneous microsatellite polymorphism profile 
since it was associated with five different haplotypes. The most frequent microsatellites 
haplotype 16-31-13 is found only in one chromosome of normal population (p = 6.4 10–11) 
(Table III). This association can help considerably in mutation analysis by using microsatellite 
markers after screening for F508del.
The 16-31-13 haplotype found in 50% of E1104X chromosomes was also described 
linked to 2 rare mutations, the E60X mutation in UK (12) and S549N mutation in the “Grande 
briére” population (3). Association of the same haplotype with these 3 mutations suggest a 
common origin. 
The 23-31-13 haplotype generally associated with the most common mutation F508del 
(2, 5), was not encountered in the E1104X chromosomes. However, the similarity on the 
IVS17bTA and IVS17bCA markers between this haplotype and the 16-31-13 haplotype 
would also suggest a common ancestral genetic background on which both mutations arose. 
On the other hand, the 16-30-13 and 16-30-14 haplotypes not observed in the normal 
chromosomes could be suggested as specific and sensitive haplotypes for E1104X mutation. 
The 16-30-13, 16-30-14 and 16-29-14 haplotypes seem to derive from the 16-31-13 one 
as a result of a slippage at the IVS17bTA and/or IVS17bCA markers which thus suggesting a 
fonder effect.
In our country 9.56% of CFTR mutations remain indetermined (27). In this case a 
combination of methods for mutation detection and haplotype analysis could provide rapid, 
accurate, and reliable information especially in prenatal diagnosis for couples at risk of 
having a child affected with cystic fibrosis. 
13 
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This first preliminary study of haploypes linked to E1104X mutation can be completed 
by the analysis of a large sample of patients with E1104X mutation and other mutations 
found in Tunisia.
Knowledge of CFTR mutation haplotypes in our population would significantly facilitate 
mutation diagnosis.
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